A new report by the European Centres for Disease Control (ECDC) and World Health Organization (WHO) shows that prevention efforts are failing, particularly in Central and Eastern Europe, as the number of people living with HIV in Europe reaches over 2 million for the first time.
The UK has exceeded UNAIDS Fast-Track targets of getting people on treatment and virally suppressed, but falls behind on reaching those who are undiagnosed.
A number of southern African countries are making good progress towards the 90-90-90 Fast-Track Targets, but efforts to reach younger populations need to be redoubled.
One of the first studies into viral communication shows that viruses that infect bacteria (phages) leave chemical messages for each other which help them decide whether to kill or linger. Disrupting these messages could provide a new way to control HIV.
HIV as a risk factor for diabetes has long been controversial, but new evidence shows that people living with HIV have increased diabetes prevalence compared to the general population.
Targeting the human genes that HIV takes over and uses to replicate could provide a new approach to HIV treatment and suppression although more research is required.
Identifying individuals at high risk of disengaging with HIV care remains an important strategy for realising the benefits of antiretroviral treatment for public health.
Mixed-status couples using PrEP could benefit from HIV self-testing as a way to quickly diagnose any new infections and reduce frequency of clinic visits.
People with disabilities in developing countries are at high risk of HIV infection with HIV prevalence nearly double that than among those without disabilities.
Testing all patients is vital if the proportion of HIV co-infections is to fall in the European Union and European Economic Area, the World Health Organization has announced ahead of World TB Day 2017.
Initial trials using nanotechnology have shown that people living with HIV could reduce the dose of their medication by up to two-thirds with no loss of effectiveness - which could improve adherence and reduce costs.
Digital intervention shows success linking hidden, at-risk men who have sex with men (MSM) and transgender women with HIV testing and PrEP services – and has the potential to be replicated elsewhere with high internet penetration.
Weaker health systems and psychosocial factors may explain the differences in adherence patterns between Asia and Africa, the world’s two most HIV-affected regions.
Most healthcare providers cite worries over risk compensation after providing HIV prevention drug PrEP, but experiences among doctors who do prescribe PrEP are positive.
As prescription opioid addiction continues to increase in the USA researchers predict a rising epidemic of injecting-related diseases such as HIV and hepatitis.